A Single Ascending Dose and Multiple Ascending Dose Phase 1 Study of PXS-5505A Administered Orally in Healthy Adult Males

Exclusion Criteria22

• Clinically significant abnormal findings on the physical examination or medical history
• Clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, skin or cardiovascular disease or any other condition, that, in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
• History of immediate hypersensitivity to any medication or currently suffers from clinically significant systemic allergic disease.
• Presence of a currently healing wound, recent musculoskeletal injury or currently healing fracture.
• Have received or is anticipated to receive any prescription systemic or topical medication within 14 days prior to the start of dosing or within 5 half-lives of the drug, or use of any over-the-counter, complementary or alternative medicine 48 hours prior to the start of dosing
• At Investigator discretion if systolic blood pressure less than 100 or greater than 160 mmHg, diastolic blood pressure less than 50 or greater than 95 mmHg and heart rate (HR) less than 45 or greater than 100 beats per minute.
• Alanine aminotransferase (ALT), aspartate transaminase (AST), or bilirubin greater than 1.5x upper limit of normal (ULN).
• Haemoglobin (Hb), white blood cells (WBC), neutrophils, platelets less than LLN.
• Evidence of significant renal insufficiency
• Positive screening test for Hepatitis B surface antigen or Hepatitis C antibody or human immunodeficiency virus (HIV).
• History of drug abuse in the last 2 years.
• Males who regularly drink more than 3 units of alcohol daily
• Used nicotine-containing products
• Unable to abstain from consuming caffeine and/or xanthine products
• Consumption of grapefruit, grapefruit juice, star fruit, oranges, orange juice, Seville oranges, apple juice, red wine or other alcohol within 7 days prior to administration of study drug until 24 hours after the last dose is administered to the subject.
• Positive urine screen for drugs of abuse and alcohol breath test
• Receipt of blood or blood products, or loss or donation of 450 mL or more of blood within 90 days before the first dose administration.
• Any condition that would interfere with drug absorption
• Have participated in a clinical trial or have received an experimental therapy within 30 days or 5 half-lives of the drug,
• Systemic infection other than common cold in the week prior to dosing.
• Have received any vaccines within 30 days before the first dose administration and during the conduct of the study.
• Consumption of foods containing appreciable amounts of collagen, including meats, meat products, gravy, confectionary and ice-cream containing gelatin,